Interest of Azithromycin With or Without Hydroxychloroquine for the Treatment of COVID-19 Pneumonia : a Retrospective Observational Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 132
- 试验地点
- 1
- 主要终点
- Favorable outcome
研究概览
简要总结
During COVID-19 epidemic, hydroxychloroquine was proposed and authorized as a possible key agent in the treatment of COVID-19 hospitalized pneumonia, including in France. Gautret et al. proposed the combination regimen with azithromycin. However only one study reported the interest of azithromycin alone.
Retrospective study reporting the impact of the anti-infective agents used during the pandemic in a tertiary care hospital, using azithromycin with or without hydroxychloroquine.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •aged over 18 years old
- •hospitalized for a COVID-19 pneumonia documented by PCR or lung tomodensitometry,
- •admitted outside an intensive care unit, in a medicine ward
排除标准
- •patient opposed to data collected, or who could not consent because of a serious presentation of the pneumonia
研究组 & 干预措施
Azithromycin or non-azithromycin group
Patient who received during admission for a severe COVID-19 pneumonia, azithromycin +/-hydroxychloroquine or no azithromycin.
干预措施: favorable outcome (Drug)
结局指标
主要结局
Favorable outcome
时间窗: Assessed within 7 days after admission
After being admitted, patient was monitored whether he does not required to be transferred in ICU or died because of a severe COVID-19 pneumonia within 7 days. The outcome was purely clinical. If patient was discharged at home after admission and/or was transferred into a rehabilitation center he was considered as a favorable outcome independently of any biological marker.
次要结局
- Interest of anti-infective agents(From date of inclusion until the date of first documented progression to ICU or date of death from any cause, whichever came first, assessed up to 2 months)
- Risk factors 1(Assessed at day 1)
- Risk factors 2(Assessed at day 1)